The estimated Net Worth of Karin Jooss is at least $1.46 Million dollars as of 15 May 2024. Karin Jooss owns over 13,749 units of Gritstone Bio Inc stock worth over $334,928 and over the last 6 years he sold GRTS stock worth over $44,154. In addition, he makes $1,082,300 as Executive Vice President - Research and Chief Scientific Officer at Gritstone Bio Inc.
Karin has made over 2 trades of the Gritstone Bio Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 13,749 units of GRTS stock worth $10,312 on 15 May 2024.
The largest trade he's ever made was selling 13,749 units of Gritstone Bio Inc stock on 15 May 2024 worth over $10,312. On average, Karin trades about 952 units every 45 days since 2019. As of 15 May 2024 he still owns at least 683,526 units of Gritstone Bio Inc stock.
You can see the complete history of Karin Jooss stock trades at the bottom of the page.
Dr. Karin Jooss Ph.D. serves as Executive Vice President - Research, Chief Scientific Officer of the Company. She has served as our Executive Vice President of Research and Chief Scientific Officer since April 2016. Prior to Gritstone, from May 2009 to April 2016, Dr. Jooss served as head of cancer immuno-therapeutics in the vaccine immuno-therapeutics department at Pfizer, Inc., or Pfizer, a public pharmaceutical company, where she was also a member of the vaccine immuno-therapeutics leadership team and served as head of the immuno-pharmacology team. Prior to joining Pfizer, Dr. Jooss served as vice president of research at Cell Genesys, Inc., or Cell Genesys, from June 2005 to April 2009, and as senior director of research at Cell Genesys from July 2001 to June 2005. She is on the editorial board of Molecular Therapy and the Journal of Gene Medicine and is a member of the Immunology and Educational Committee of the American Society of Gene & Cell Therapy and the Industry Task Force of the Society for Immunotherapy of Cancer. Dr. Jooss has served on the board of directors of Fate Therapeutics, Inc., a publicly traded biopharmaceutical company, since March 2019. Dr. Jooss received her diploma in theoretical medicine from the University of Marburg in Germany, a Ph.D. in molecular biology and immunology from the University of Marburg in Germany and performed postgraduate work in gene therapy and immunology at the University of Pennsylvania.
As the Executive Vice President - Research and Chief Scientific Officer of Gritstone Bio Inc, the total compensation of Karin Jooss at Gritstone Bio Inc is $1,082,300. There are 3 executives at Gritstone Bio Inc getting paid more, with Andrew Allen having the highest compensation of $2,187,440.
Karin Jooss is 55, he's been the Executive Vice President - Research and Chief Scientific Officer of Gritstone Bio Inc since 2016. There are 5 older and 14 younger executives at Gritstone Bio Inc. The oldest executive at Gritstone Bio Inc is Alan C. Mendelson J.D., 71, who is the Sec..
Karin's mailing address filed with the SEC is C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131.
Over the last 6 years, insiders at Gritstone Bio Inc have traded over $277,077 worth of Gritstone Bio Inc stock and bought 2,026,375 units worth $15,022,790 . The most active insiders traders include Group, Llc Green Jeremy Red..., Peter Svennilson, and Thomas Woiwode. On average, Gritstone Bio Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,654. The most recent stock trade was executed by Andrew R Allen on 15 May 2024, trading 24,263 units of GRTS stock currently worth $18,197.
gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.
Gritstone Bio Inc executives and other stock owners filed with the SEC include: